EUVIMEDEUVIMED entdecken
Crossref

Tirzepatide vs Insulin Lispro TID Added-On to Poorly Controlled Basal Insulin-Treated Type 2 Diabetes

Julio Rosenstock, Juan Frias, Helena Rodbard, Santiago Tofé, Emmalee Sears, Ruth Huh, Laura Fernández Landó, Hiren Patel, Jörg Simon

Diabetologie und Stoffwechsel · 01.04.2024 · 19 (S 01 S 01) · S76-S77

DOI: 10.1055/s-0044-1785381 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetologie und Stoffwechsel, erschienen am 01.04.2024. Verfasst von Julio Rosenstock und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Is adding tirzepatide (TZP) superior to insulin lispro TID for glycemic control in patients with long-standing type 2 diabetes (T2D) and poor glycemic control in spite of optimized basal insulin treatment with or without metformin?

Methods

In this 52 week open-label, multicentre, Phase 3b study, 1428 patients with T2D (mean baseline [BL] age 59 years; T2D duration 14 years; HbA1C 72.67 mmol/mol (8.80%); BMI 33 kg/m2; insulin glargine (iGlar) dose-46 IU/day) were randomised (1:1:1:3) to TZP (5, 10, 15 mg) or insulin lispro (iLispro) TID, as an add-on to iGlar±metformin. Insulin doses were titrated to a target fasting and pre-prandial glucose of 100-125 mg/dL. Primary and secondary efficacy measures were change in HbA1C from BL for TZP (pooled) vs iLispro at 52 weeks, change from BL in body weight (BW), and proportion of patients at HbA1C and BW loss goals (TZP pooled and each dose vs iLispro).

Results

TZP (pooled) was superior vs iLispro in change from BL in HbA1C, achieving a mean HbA1C of 47.53 mmol/mol vs 59.55 mmol/mol, BW loss of 10 kg vs gain of 4 kg, with less insulin use (iGlar: 13 IU/day vs 42 IU/day [iLispro 62 IU/day]) respectively. Rate of Level 2 and 3 hypoglycemia was 10-fold higher with iLispro. The most common adverse events with TZP were nausea, diarrhea, and vomiting mostly of mild to moderate severity.

Conclusions

TZP demonstrated clinically meaningful and superior glycemic and BW control vs iLispro associated with less clinically significant hypoglycemia. Publication History Article published online: 18 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Rosenstock, J., Frias, J., Rodbard, H., Tofé, S., Sears, E., Huh, R., Landó, L. F., Patel, H., & Simon, J. (2024). Tirzepatide vs Insulin Lispro TID Added-On to Poorly Controlled Basal Insulin-Treated Type 2 Diabetes. Diabetologie und Stoffwechsel, 19(S 01 S 01), S76-S77. https://doi.org/10.1055/s-0044-1785381

Vancouver

Rosenstock J, Frias J, Rodbard H, Tofé S, Sears E, Huh R, et al. Tirzepatide vs Insulin Lispro TID Added-On to Poorly Controlled Basal Insulin-Treated Type 2 Diabetes. Diabetologie und Stoffwechsel. 2024;19(S 01 S 01):S76-S77. doi:10.1055/s-0044-1785381

BibTeX
@article{Rosenstock2024,
  author = {Rosenstock, Julio and Frias, Juan and Rodbard, Helena and Tofé, Santiago and Sears, Emmalee and Huh, Ruth and Landó, Laura Fernández and Patel, Hiren and Simon, Jörg},
  title = {Tirzepatide vs Insulin Lispro TID Added-On to Poorly Controlled Basal Insulin-Treated Type 2 Diabetes},
  journal = {Diabetologie und Stoffwechsel},
  year = {2024},
  volume = {19},
  number = {S 01 S 01},
  pages = {S76--S77},
  doi = {10.1055/s-0044-1785381}
}
Kostenlos starten →